This fact sheet outlines IQVIA’s HTA and payer submission services in Canada, focusing on helping organizations achieve successful reimbursement outcomes. It emphasizes the importance of navigating the complex evaluation processes of key HTA bodies such as Canada’s Drug Agency (CDA) and INESSS, as well as engaging with up to 30 private payers. IQVIA provides end-to-end support, from evidence generation and economic modeling to submission development and post-submission engagement. Their approach integrates real-world evidence, stakeholder insights, and payer-specific value narratives to strengthen submissions and maximize market access. By aligning clinical, economic, and strategic components, IQVIA helps clients move efficiently from regulatory approval to positive reimbursement decisions

Join for free to read